The overall growth of the superdisintegrants market<\a> is driven mainly by the increasing adoption of orally disintegrating tablets (ODT), growing generics market, and the emergence of new superdisintegrants for the pharmaceutical industry. The shifting focus of pharmaceutical manufacturing to emerging markets and the growth of the overall pharmaceutical sector in these markets present significant opportunities for the superdisintegrants market growth. However, safety and quality concerns are expected to challenge the market growth to a certain extent during the forecast period.
Theglobal superdisintegrants market is projected to reach USD 536.5 million by 2023from USD 366.4 million in 2018, at a CAGR of 7.9%.
In this report, the market is segmented by type, formulation, therapeutic area, and region.
By type, the global superdisintegrants market is segmented into natural superdisintegrants, synthetic superdisintegrants, and other superdisintegrants. Synthetic superdisintegrants accounted for the largest share of the superdisintegrants market in 2017. The large share of this segment is attributed to the increasing number of companies manufacturing synthetic superdisintegrants due to their widespread usage in various pharmaceutical formulations.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=198068672<\a>
By formulation, the superdisintegrants market is segmented into tablets and capsules. The tablets segment accounted for the larger share of the superdisintegrants market in 2017. The large share of this segment can be attributed to the widespread use of ODTs and fast-disintegrating tablets (FDTs) among healthcare providers and patients, resulting in the large-scale manufacture of these products by pharmaceutical manufacturers. The high demand for such ODTs and FDTs can be attributed to their advantages such as increasing drug bioavailability, better pregastric absorption, ease of swallowing in patients with dysphagia, ease of administration, and improved shelf life.
Based on therapeutic area, the superdisintegrants market is segmented into gastrointestinal diseases, neurological diseases, oncology, infectious diseases, cardiovascular disease, hematological diseases, and inflammatory diseases. Neurological diseases accounted for the largest share of the superdisintegrants market in 2017. This segment is also expected to witness the highest growth during the forecast period. The large share of the neurological diseases segment is attributed to the extensive usage of superdisintegrants in the formulation of ODTs for antidepressants, antipsychotics, antimigraine, and sedatives used in the treatment of neurological conditions.
The superdisintegrants market in the APAC region is expected to register the highest CAGR during the forecast period. Several factors, such as the region’s growing scientific base and capabilities, growth in the Asian pharmaceutical markets and pharmaceutical manufacturing capabilities, and the large patient pool are contributing to the growth of the superdisintegrants market in the region. The region is witnessing an increasing number of investments by major market players to leverage the high-growth opportunities provided by emerging markets such as China and India.
Speak To Analyst @https://www.marketsandmarkets.com/speaktoanalyst.asp?id=198068672<\a>
